OXFORD, United Kingdom - Barinthus Biotherapeutics plc (NASDAQ: BRNS) has initiated a Phase 1 trial for VTP-1000, an investigational immunotherapy for celiac disease. The clinical-stage biopharmaceutical company is focused on developing treatments that guide T cells to control disease. The AVALON trial, a randomized, placebo-controlled study, will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTP-1000 in adults with celiac disease.
The trial will enroll 42 participants and is structured in two parts: a single ascending dose phase followed by a multiple ascending dose phase, which includes a controlled gluten challenge to evaluate the therapy's effects on gluten exposure. VTP-1000 utilizes Barinthus Bio's proprietary SNAP-TI platform to deliver gluten-derived peptide antigens and the immunomodulator rapamycin to promote immune tolerance.
Celiac disease affects approximately one in 100 people globally and is characterized by an autoimmune response to dietary gluten, causing inflammation and damage to the small intestine. Currently, there are no approved treatments for the disease, and management primarily involves strict gluten avoidance, which can be challenging due to its widespread presence in foods.
Dr. Leon Hooftman, Chief Medical Officer, emphasized the burden of the disease on patients' daily lives due to the difficulty in avoiding gluten and the lack of approved treatments. Dr. Nadège Pelletier, Chief Scientific Officer, expressed optimism about bringing the SNAP-TI platform into the clinic with VTP-1000, aiming to restore immune tolerance to gluten.
Barinthus Bio is also advancing other immunotherapeutic product candidates for chronic infectious diseases and autoimmunity, including VTP-300 for chronic HBV infection and VTP-850 for recurrent prostate cancer.
This announcement is based on a press release statement and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.
In other recent news, Barinthus Biotherapeutics has reported several key developments. The company announced the promotion of Graham Griffiths to Chief Operating Officer, a move that reflects an internal restructuring. Griffiths brings significant industry experience to his new role, having previously served as the company's Chief Business Officer and co-founder of Agalimmune Limited.
In addition to the leadership change, Barinthus Biotherapeutics has made strategic adjustments to its pipeline. The company is now prioritizing the development of VTP-300 for chronic Hepatitis B and VTP-1000 for celiac disease, following encouraging trial results. This strategic shift has led H.C. Wainwright to revise its price target for the company, while maintaining a Buy rating.
Further, Barinthus Biotherapeutics has announced a workforce reduction of approximately 25%, a decision expected to extend the company's cash runway into the second quarter of 2026. Concurrently, the company welcomed Dr. Leon Hooftman as its new Chief Medical Officer. Finally, mixed results were reported from the APOLLO trial of VTP-200, a treatment for cervical lesions associated with high-risk HPV infections.
InvestingPro Insights
As Barinthus Biotherapeutics plc (NASDAQ: BRNS) embarks on its Phase 1 trial for VTP-1000, potential investors and industry observers are closely monitoring the company's financial health and market performance. According to InvestingPro, BRNS holds more cash than debt on its balance sheet, which can be a positive sign of financial stability as it advances its clinical trials. However, analysts are not optimistic about the company's profitability in the near term, as they do not anticipate BRNS to be profitable this year.
InvestingPro Data reveals a market capitalization of $47.3 million, indicating the size of the company in the competitive biopharmaceutical landscape. The Price to Earnings (P/E) Ratio stands at -0.79, reflecting the company's current lack of earnings. Additionally, the stock price has taken a significant hit over the last six months, declining by 53.49%, which may reflect investor concerns about the company's cash burn and the challenges ahead.
For those considering an investment in BRNS, the InvestingPro platform offers a comprehensive list of tips and metrics to help make informed decisions. There are 10 additional InvestingPro Tips available, which provide deeper insights into the company's financial health and market expectations.
Investors may also note that BRNS does not pay a dividend, which could influence decisions for income-focused portfolios. The company's efforts in advancing treatments for celiac disease and other conditions are pivotal, and the financial metrics provided by InvestingPro can help stakeholders understand the risks and opportunities associated with BRNS's journey in the biopharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.